Description: CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Home Page: www.cytomx.com
151 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 515 3185
Officers
| Name | Title |
|---|---|
| Dr. Sean A. McCarthy DPHIL | Chairman & CEO |
| Dr. Marcia P. Belvin Ph.D. | Senior VP & Chief Scientific Officer |
| Mr. Jeffrey Landau B.S., M.B.A. | Senior VP, Head of Strategy & Chief Business Officer |
| Mr. Christopher W. Ogden | Chief Financial Officer |
| Mr. Lloyd A. Rowland Jr., J.D. | Senior VP, General Counsel, Chief Compliance Officer & Secretary |
| Ms. Danielle Olander-Moghadassian | Senior VP & Chief Human Resources Officer |
| Ms. Leslie Robbins | Senior Vice President of Intellectual Property |
| Dr. Yu-Waye Chu M.D. | Chief Medical Officer |
| Ms. Dawn Benson | Senior Vice President of Quality & Product Manufacturing |
| Dr. Hoyoung Huh M.D., Ph.D. | Special Advisor to Chief Executive Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 13.5501 |
|---|---|
| Trailing PE: | 7.1733 |
| Price-to-Book MRQ: | 4.7628 |
| Price-to-Sales TTM: | 0.682 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 120 |